INmune Bio, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, August 7, 2026 at 7:37 AM GMT+3 3 min read

INmune Bio, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Execution and Platform De-risking

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Achieved formal MHRA alignment on the Ebstracel regulatory package, covering CMC, nonclinical, and clinical evidence to support a conditional marketing authorization application.
Secured pediatric investigation plan approval in under three months, with regulators recognizing MISSION EB data as demonstrating clinically meaningful benefits in pain and pruritus.
Completed a critical commercial manufacturing milestone by successfully processing the first commercial-ready umbilical cord and transferring master cell bank production to a registration-intended facility.
Strengthened the CORDStrom platform's supply chain through an expanded agreement with Anthony Nolan, providing scalable access to qualified tissue for UK, EU, and US markets.
Validated XPro's mechanism in Alzheimer's disease via statistically significant treatment effects on white matter myelin MRI biomarkers (p=0.0028) in the full intent-to-treat population.
Maintained a disciplined capital allocation strategy, utilizing Australian R&D tax rebates to offset expenses and minimize shareholder dilution while focusing resources on the RDEB program.

Regulatory Timeline and Commercial Readiness

Expect to submit the Ebstracel MAA to the UK MHRA by late Q3 or early Q4 2026, followed by an EMA submission in early 2027.
Planned US BLA submission for Ebstracel is targeted for Q1 2027, seeking conditional approval supported by orphan drug and rare pediatric disease designations.
Anticipate initiating a Phase 3 confirmatory safety trial for Ebstracel involving 40 to 45 patients, with data expected by mid-2028.
Projecting UK commercial revenue potential starting in Q2 2027, with pricing negotiations expected to align with US benchmarks of $400,000 to $500,000 per year per child.
Evaluating strategic partnerships for the XPro platform to accelerate development in Alzheimer's and other indications while preserving core value for shareholders.

Financial and Structural Developments

Reported a significant reduction in net loss to $1.3 million, primarily due to the absence of prior-year impairment charges and the recognition of Australian R&D rebates.
Confirmed cash runway into Q2 2027, supported by $18.4 million in cash and a subsequent $4.2 million R&D tax rebate received after the quarter's end.
Highlighted the potential value of a Priority Review Voucher (PRV) upon US approval, noting recent secondary market transactions between $150 million and $200 million.
Established a Scientific Advisory Board to prioritize CORDStrom platform expansion into additional disease-specific applications beyond RDEB.

Q&A Session Insights

Clarification of Phase 3 confirmatory trial design and timeline

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

The trial will serve as both a safety and confirmatory study, enrolling approximately 40 to 45 patients at a rate of 1-2 patients per week.
The study involves six total infusions per year (two infusions every 10 days, three times annually) with data expected by mid-2028.

Regulatory focus on pain and pruritus as primary endpoints

Management emphasized that itch and pain are the top patient concerns and are directly linked to wound healing and infection prevention.
Regulators across all three jurisdictions have recognized these symptomatic benefits as clinically meaningful for RDEB patients.

UK commercial launch strategy and patient reach

The company expects to reach approximately 100 patients in the UK within two years of approval by leveraging existing relationships with leading children's hospitals.
Reimbursement can potentially be secured through hospital budgeting processes even before formal national price negotiations are finalized.

Capital strategy and management's approach to dilution

Management expressed high sensitivity to dilution as founders and major shareholders, aiming for a 'judicious' and 'prudent' fundraising approach.
The company is actively transitioning its investor base from Alzheimer's-focused shareholders to those specializing in rare diseases.